BARNES KEITH

September 7, 2026

Knowles faces mixed signals with insider sale and analyst caution. Knowles is in focus this week as it prepares to attend the Midwest IDEAS Conference, with discussion building around what counts as a fair value for the stock. At the same time, several analyst pieces are highlighting concerns about the company's risk profile, with one naming Knowles among Russell 2000 names to avoid and another suggesting investors look at a different stock instead. Adding to the picture, company Director Shavers sold $260,000 worth of stock. The stock is trading near the middle of its 52-week range, with a trailing P/E well above peers and an average analyst price target of $43.75.

October 5, 2026

VIAV Highlights New 100G Testing Platform and CF50 Product. Viavi Solutions highlighted its latest 100G testing platform and the CF50 product in recent releases, signaling a push into enterprise‑scale and AI inference markets. A Yahoo article noted the company’s more than threefold growth over the past year, while a Q2 review compared its performance to peers. These updates underscore Viavi’s ongoing expansion in high‑speed testing technology.

October 12, 2026

Roche presents new Phase III data and FDA approval. Roche reported new one-year Phase III data for vamikibart in treating uveitic macular edema, a condition causing vision loss. Additionally, the FDA approved Tecentriq for adjuvant treatment of stage III colon cancer. These developments reflect ongoing progress in the company's clinical pipeline and regulatory approvals.